100,000 Shares in Lyell Immunopharma, Inc. $LYEL Bought by RBF Capital LLC

RBF Capital LLC bought a new position in shares of Lyell Immunopharma, Inc. (NASDAQ:LYEL) in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm bought 100,000 shares of the company’s stock, valued at approximately $884,000. RBF Capital LLC owned about 0.65% of Lyell Immunopharma as of its most recent SEC filing.

A number of other institutional investors have also recently made changes to their positions in LYEL. Almitas Capital LLC raised its position in shares of Lyell Immunopharma by 136.3% during the first quarter. Almitas Capital LLC now owns 2,482,606 shares of the company’s stock worth $1,336,000 after acquiring an additional 1,432,086 shares during the last quarter. Nuveen LLC acquired a new stake in Lyell Immunopharma during the 1st quarter valued at approximately $345,000. Acadian Asset Management LLC lifted its position in shares of Lyell Immunopharma by 204.2% in the 1st quarter. Acadian Asset Management LLC now owns 660,899 shares of the company’s stock worth $354,000 after purchasing an additional 443,614 shares during the period. Walleye Capital LLC bought a new stake in shares of Lyell Immunopharma in the 2nd quarter valued at $258,000. Finally, AQR Capital Management LLC increased its position in shares of Lyell Immunopharma by 773.5% during the first quarter. AQR Capital Management LLC now owns 174,279 shares of the company’s stock worth $94,000 after buying an additional 154,327 shares during the period. Institutional investors own 66.05% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts recently issued reports on the stock. Wall Street Zen upgraded shares of Lyell Immunopharma from a “sell” rating to a “hold” rating in a report on Monday, September 1st. HC Wainwright raised Lyell Immunopharma from a “neutral” rating to a “buy” rating and boosted their price objective for the company from $20.00 to $45.00 in a research note on Tuesday. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Lyell Immunopharma in a research note on Wednesday, October 8th. One research analyst has rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Lyell Immunopharma currently has an average rating of “Hold” and an average price target of $45.00.

Lyell Immunopharma Trading Up 3.2%

Shares of NASDAQ LYEL opened at $29.27 on Wednesday. The firm’s 50-day moving average price is $18.96 and its 200-day moving average price is $13.65. Lyell Immunopharma, Inc. has a 1-year low of $7.65 and a 1-year high of $30.00. The firm has a market capitalization of $621.69 million, a P/E ratio of -1.27 and a beta of -0.11.

Lyell Immunopharma (NASDAQ:LYEL) last issued its earnings results on Wednesday, November 12th. The company reported ($2.13) EPS for the quarter, beating analysts’ consensus estimates of ($2.81) by $0.68. Lyell Immunopharma had a negative return on equity of 96.68% and a negative net margin of 794,292.69%.The business had revenue of $0.02 million during the quarter, compared to analyst estimates of $0.01 million. Equities research analysts forecast that Lyell Immunopharma, Inc. will post -0.78 EPS for the current year.

Lyell Immunopharma Company Profile

Lyell Immunopharma, Inc, a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic.